RheumaView™ spans a deliberately broad analytical horizon. Each research domain listed below represents a distinct area of structured radiographic intelligence — supported by the same validator-governed deterministic architecture, the same dual clinical/research layer separation, and the same commitment to reproducibility.
What is shown here is the public surface. Each domain extends deeper into proprietary analytic territory available under partnership and NDA.
Inflammatory & Autoimmune Arthritis
The domain that started it all. Rheumatoid arthritis, psoriatic arthritis, axial and peripheral spondyloarthritis — analyzed through structured longitudinal tracking, phenotype-level differentiation, and treatment-response correlation. RheumaView™ does not merely score joints. It builds a governed structural narrative across timepoints, separating true inflammatory progression from degenerative drift, and producing research-grade endpoints suitable for clinical trials.
Case illustrations published. Active pharmaceutical relevance.
Degenerative & Mechanical Disease
Osteoarthritis, degenerative disc disease, spondylosis, DISH, and mechanical joint deterioration — assessed with projection-normalized structural scoring and compartmental analysis. The platform differentiates inflammatory from degenerative patterns with deterministic precision, addressing one of radiology’s most persistent diagnostic gray zones. For pharma sponsors running OA trials, this means cleaner cohort stratification and more defensible endpoints.
Case illustrations published.
Spine & Neuroradiology
Cervical, thoracic, and lumbar spine — evaluated across modalities with structured cross-modality concordance between plain radiographs and MRI. The platform maps neuro-structural relationships, correlating imaging findings with functional indicators. Instability analysis, canal evaluation, foraminal assessment — all within a governed, reproducible framework. For spine surgery planning, clinical trials, and insurance documentation, this domain delivers structured evidence where narrative variability has been the norm.
Case illustrations published. Cross-modality concordance demonstrated.
Metabolic Bone Disease
Mineralization analytics derived from plain radiographs — not as a replacement for densitometry, but as a structured, reproducible complementary layer. Osteoporosis indicators, metabolic pattern recognition, DXA–radiograph concordance, Paget’s disease, and therapy-response tracking. For health systems and pharmaceutical sponsors, this domain offers a governed pathway to extract metabolic bone intelligence from imaging studies that are already being acquired.
Domain active. Case documentation in preparation.
Pediatric Musculoskeletal Imaging
Children are not small adults — and their imaging should not be analyzed with adult-calibrated tools. RheumaView™ provides developmental normalization with age-indexed variance modeling, growth trajectory analysis, and pediatric-specific structural assessment. This domain addresses a significant gap in current imaging analytics, where pediatric studies are typically read without formal developmental adjustment. For pediatric rheumatology, orthopedics, and endocrinology research, this is a category that barely exists elsewhere.
Domain active. Normalization framework documented.
Orthopedics & Trauma
Fracture characterization, post-surgical structural assessment, alignment analysis, hardware evaluation, and biomechanical load inference — all within the same deterministic, validator-governed framework. For orthopedic practices, hospital systems, and trauma centers, RheumaView™ offers a structured alternative to variable narrative reporting. For post-operative surveillance and longitudinal outcome tracking, the platform provides reproducible, quantifiable outputs.
Domain active. Cases in preparation.
Clinical Trial Imaging
This is not a specialty — it is a use case that cuts across all domains. Harmonized multi-site endpoints, reproducible longitudinal scoring, trial-compatible structured export, and cross-reader consistency verification. RheumaView™ was designed from the ground up to produce outputs that survive regulatory scrutiny. For pharmaceutical sponsors and CROs managing multi-center imaging trials, the platform eliminates the variability problem at its architectural root.
Endpoint architecture documented. Pharma-ready.
Cross-Modality & Quantitative Research
The research layer that runs beneath all clinical output. Multi-modal integration across X-ray, MRI, CT, and DXA. Quantitative extraction, phenotype-level pattern analysis, longitudinal drift computation, and research-grade analytics — all deterministic, all traceable, all exportable. For academic researchers, biostatisticians, and translational teams, this layer transforms imaging from a qualitative narrative into a governed quantitative data source.
Methodology published. Research extraction framework active.
Each domain operates within RheumaView™’s unified validator-governed architecture. All outputs maintain deterministic lineage, clinical–research layer separation, and full audit traceability.
For detailed domain-specific capabilities, case illustrations, and partnership discussions, please contact us.